What question did this study set out to answer?

To evaluate the efficacy and safety of secukinumab over 52 weeks in Japanese patients diagnosed with generalized pustular psoriasis.

February 26, 2016The Journal of Dermatology

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese study

View Full Paper

Ask AI

Bookmark

Authors

SIShinichi ImafukuFukuoka University MHMasaru HonmaAsahikawa Medical University YOYukari OkuboTokyo Medical University

Discussion

Member takes

Implication

Open-label phase III trial demonstrates rapid and sustained disease clearance with secukinumab in generalized pustular psoriasis, highlighting a potent therapeutic option.

Key Points

To evaluate the efficacy and safety of secukinumab over 52 weeks in Japanese patients diagnosed with generalized pustular psoriasis.
Conducted a phase III, open-label, multicenter, single-arm trial enrolling 12 Japanese patients with generalized pustular psoriasis receiving secukinumab monotherapy or co-medication.
Administered subcutaneous secukinumab 150 mg at baseline, weeks 1, 2, 3, and 4, and every 4 weeks thereafter through 52 weeks, with non-responders up-titrated to 300 mg.
Assessed changes in disease severity using the Clinical Global Impression (CGI) scale, with the primary endpoint set at week 16.
Treatment success was achieved by 83.3% of patients (n = 10/12) at week 16, with 9 patients rated as 'very much improved' and 1 as 'much improved'.
Erythema and pustule resolution began as early as week 1, resolved in most patients by week 16, and remained sustained through week 52.
Secukinumab was well tolerated over 52 weeks without unexpected safety signals; frequent adverse events included nasopharyngitis, urticaria, diabetes mellitus, and arthralgia.

Cite This Study

Imafuku et al. (2016) studied this question.

synapsesocial.com/papers/6a8a75759be9d02581bdb1ef https://doi.org/10.1111/1346-8138.13306

View Full Paper

Ask AI

Bookmark

Implication

Open-label phase III trial demonstrates rapid and sustained disease clearance with secukinumab in generalized pustular psoriasis, highlighting a potent therapeutic option.

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese study

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider